Genotyping
lung cancer, NELSON
LUNG CANCER
To address the 1st objective, genotyping of the NELSON CT-screening cohort will be completed. Of the NELSON CT screening cohort with blood sampling (N = 6,803), about 40% has previously been genotyped with arrays. DNA genotyping of the remaining 60% will be conducted. This effort will provide a comprehensive genetic profile of the NELSON CT screening cohort, which can be used to assess the role of various genetic variations, to construct polygenic risk scores (PRSs). For lung cancer, the genetic variants identified by the most recent genome-wide association study (GWAS) will be combined [463 Single Nucleotide Polymorphisms (SNPs)] to allow maximum predictive power [After array genotyping, the dataset will be imputed to reference data (i.e. the 1000 Genomes resource [